NeuroSense Therapeutics (NRSN) Cash & Current Investments (2020 - 2025)
NeuroSense Therapeutics (NRSN) posted Cash & Current Investments of $213000.0 for Q4 2025, down 69.96% sequentially from $709000.0 in Q2 2025, and down 93.76% YoY from $3.4 million in Q4 2024.
NeuroSense Therapeutics (NRSN) Cash & Current Investments (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Cash & Current Investments for 6 years, with the latest figure at $213000.0 in Q4 2025.
- Quarterly Cash & Current Investments fell 93.76% year-over-year to $213000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $213000.0 (down 93.76% YoY) and the FY2025 annual result came in at $213000.0, down 93.76% from the prior year.
- Cash & Current Investments fell to $213000.0 in Q4 2025 per NRSN's latest filing, from $709000.0 in the prior quarter.
- Over five years, Cash & Current Investments peaked at $11.1 million in Q4 2022 and troughed at $213000.0 in Q4 2025.
- A 5-year average of $3.3 million and a median of $2.0 million in 2023 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2022 and 2025: Cash & Current Investments jumped 1403.93% in 2022, then slumped 93.76% in 2025.
- Over 5 years, Cash & Current Investments stood at $738000.0 in 2021, then surged by 1403.93% to $11.1 million in 2022, then plunged by 75.85% to $2.7 million in 2023, then rose by 27.35% to $3.4 million in 2024, then plunged by 93.76% to $213000.0 in 2025.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $213000.0, $709000.0, and $3.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 213,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 213,000.00 |
| Jun 30, 2025 | 709,000.00 |
| Dec 31, 2024 | 3.41 Mn |
| Sep 30, 2024 | 344,000.00 |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 735,000.00 |
| Dec 31, 2023 | 2.68 Mn |
| Sep 30, 2023 | 4.76 Mn |
| Jun 30, 2023 | 7.09 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 11.10 Mn |
| Sep 30, 2022 | 4.43 Mn |
| Jun 30, 2022 | 4.37 Mn |
| Mar 31, 2022 | 8.80 Mn |
| Dec 31, 2021 | 738,000.00 |
| Jun 30, 2021 | 994,000.00 |
| Dec 31, 2020 | 699,000.00 |